Alder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of four CGRP-class antibodies developed to treat the condition.
People suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig if they fail other therapies, according to the country’s cost-effectiveness
Novartis and Amgen have become embroiled in a legal row over rights to the migraine prevention drug Aimovig, as sales of a new class of injected drugs begin to mount.
